Dutch venture builder NLC has announced a €20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s targeting a final close of €100m later this year.
Generic and biosimilar manufacturer Sandoz is expanding with a new biologics production facility in Lendava, Slovenia to prepare for more demand in Europe for biosimilar products.
The Sweden Biobank Act governs the collection, storage, and usage of identifiable human material samples for specific purposes.
The Innovative Health Initiative (IHI) Governing Board has appointed Niklas Blomberg to be the next Executive Director of the organisation. Dr Blomberg has extensive experience of working in Europes life science sector, and is currently Director of ELIXIR, the European life sciences data infrastructure. He will take up his duties at IHI in early 2024.
Six years after the first approved cell and gene therapy, the field is living a renaissance. 5 additional FDA-approved therapies were added in 2022 and could be doubled in 2023, setting a new pace to cell & gene therapies. The BioRN Annual Conference on September 29th in Heidelberg will highlight next-generation approaches in the field.
Six years after the first approved cell and gene therapy, the field is living a renaissance. 5 additional FDA-approved therapies were added in 2022 and could be doubled in 2023, setting a new pace to cell & gene therapies. The BioRN Annual Conference on September 29th in Heidelberg will highlight next-generation approaches in the field.
Carthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its €37.5m ($40m) Series B financing round.